{"id":"W2805363969","doi":"10.1200/jco.2018.36.18_suppl.lba1006","title":"Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) <i>v</i> FULV in patients (pts) with estrogen receptor (ER)-positive, <i>PIK3CA</i> -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Ottawa Hospital","funders":"","keywords":"Fulvestrant; Medicine; Metastatic breast cancer; Internal medicine; Clinical endpoint; Hazard ratio; Adverse effect; Oncology; Population; Randomized controlled trial; Cancer; Breast cancer; Placebo; Progression-free survival; Estrogen receptor; Confidence interval; Overall survival; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001811644,0.0005527406,0.004731328,0.0004982658,0.00008938895,0.00001737799,0.0004916049,0.0002925983,0.0008659762],"category_scores_gemma":[0.0004703025,0.0003550783,0.0006037431,0.001528882,0.000854985,0.0004845019,0.0001081161,0.001257702,0.000007486028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007446855,"about_ca_system_score_gemma":0.003199355,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004930017,"about_ca_topic_score_gemma":0.001853759,"domain_scores_codex":[0.991483,0.001023262,0.004817358,0.0007548712,0.001280561,0.000640911],"domain_scores_gemma":[0.9905584,0.001722978,0.004367364,0.0006211866,0.002000502,0.0007295684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.346207,0.05063626,0.2144692,0.00006935655,0.01416714,0.001100162,0.001514699,0.0006242607,0.003577727,0.00000330594,0.000222473,0.3674084],"study_design_scores_gemma":[0.3555254,0.2011365,0.4123382,0.001253039,0.01801751,0.000310423,0.003674246,0.0002196936,0.002053117,0.00007178188,0.004525074,0.000875049],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9936599,0.0006191469,0.00204773,0.00105913,0.0006323796,0.001254804,0.000618031,0.00002069636,0.00008823501],"genre_scores_gemma":[0.9846236,0.0004528423,0.01188537,0.002072985,0.0007352486,0.00004950769,0.00006752134,0.00007147663,0.00004142978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3665334,"threshold_uncertainty_score":0.9998901,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03734654690843785,"score_gpt":0.4099493458190268,"score_spread":0.3726027989105889,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}